Provision of free lateral flow tests could end in the UK, and prime minister Boris Johnson is expected to make the big announcement within weeks, The Sunday Times has reported.
The report said that in future free test kits could be provided only in high-risk settings such as care homes, hospitals and schools, and to people with symptoms, and contact tracing by NHS Test and Trace is also expected to be scaled back.
The newspaper quoted a senior Whitehall source as saying: "I don't think we are in a world where we can continue to hand out free lateral flow tests to everybody.
"It's likely we will move to a scenario where there is less testing, but we have a capacity to ramp it up if necessary."
It added that more than £6 billion of public money has already been spent on mass testing.
Separately, Dr Clive Dix, former chairman of the country's vaccine task force said that Covid-19 should now be treated as a flu, and mass vaccination campaigns should end after the booster shots in the UK.
To support environmental cause, natural health pioneer BetterYou has pledged its allegiance to Antarctic Quest 21 - an expedition to undertake essential exploration activities.
Under the expedition, a team of eight military and ex-military men and women will travel the untrodden regions of the Antarctic Peninsula on the 100th Anniversary
of Sir Ernest Shackleton's last Antarctic expedition.
The team will gather data for research of climate change, meteorology, geology and glaciology to enable study on recent and future environmental changes.
BetterYou will support the team with specialist equipment and smart nutritional support.
The firm has partnered with performance nutritionist, Emily Whitehead, to provide nutritional guidance and support overall wellbeing of the team pre, during and post
the expedition.
An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights
for Covid-19 interventions between the pharmaceutical industry and developing nations endures.
At the heart of the plan is a commitment to set aside part of the production of vaccines and treatments upfront for vulnerable populations in low-income countries
when the next pandemic arises, given how fragmented access to Covid tools has left many populations unprotected.
In order to do better next time - and without knowing which companies will develop the first drugs and vaccines for the next pandemic - having the industry
collectively make this commitment is potentially transformative, said Thomas Cueni, head of the International Federation of Pharmaceutical Manufacturers &
Associations (IFPMA).
The pledge, called the Berlin Declaration, was made on July 19 by members of the global pharmaceutical industry group that include many of the companies involved
in developing Covid interventions, such as AstraZeneca, GSK, Moderna, Pfizer and Merck.
The declaration is not legally binding.
However, if a company that signed on reneges on its vow, it would face grave consequences in the court of public opinion, said Cueni.
The Department of Health and Social Care (DHSC) has created a new NIHR Research Delivery Network (RDN) to support the successful delivery of health and
social care research in England.
The network, which will start operating from next year, will play a critical and active role in implementing government policies.
It will support in implementing the Life Sciences Vision, the Future of UK Clinical Research Delivery vision, and policy for life sciences research and development.
The new network would be mainly working on growing the amount of commercial clinical research as its key strategic ambition.
Also, NIHR RDN will be responding to the findings of the Lord O'Shaughnessy review, which set out a clear blueprint for how the UK can return to its global
leadership role.
Alliance Healthcare, the UK's largest pharmaceutical wholesaler, has pledged to support the global efforts to cut carbon emissions, as set out at the recent UN Climate Change Conference, COP26.
The company's pledge is in line with its aim to create "healthier futures and thebusiness", on which it has been working on for years.
It aims to become the most sustainable independent full-line pharmaceutical wholesaler in the UK by 2030, ensuring to remain the sustainable partner of choice for its customers and manufacturers.
Despite significant sales growth in the quarterly results, high street chemist Boots is moving forward with its plan to close 300 stores in the UK. The move,
aimed at improving profit margins amid rising costs and competition, will reduce the chain's portfolio from around 2,200 to just 1,900.
Last month, the U.S.-based Walgreens Boots Alliance, the parent company of Boots, announced upcoming store closures within the next year. However, the company
assured that there will be no job losses as all employees will be given the opportunity to be redeployed to nearby shops.
The following sites are confirmed for closure on the specified dates:
Heathside Rd, Woking (end of July)
UEA campus (end of July)
Hamlet Ct Rd, Westcliff-on-Sea (August 1)
Windhill Road, Wakefield (October 6)
Upper Warrengate, Wakefield (October 7)
Glastonbury (October 13)
Guildford Road, Woking (end of October)
Boots stores at Salford Shopping Centre in Greater Manchester, Church Street in Malvern, The Port Arcades Shopping Centre in Ellesmere, and King William Street
in London have already closed since spring.
A groundbreaking research project has revealed that the public is urging the government to prioritise primary and community care over hospitals.
The study also found a strong public willingness to pay higher taxes to enhance NHS services.
The Health Foundation and Ipsos UK conducted the research, combining nationwide polling with in-depth public deliberative workshops.
These workshops, held in King's Lynn, Leeds, and London, constitute one of the most comprehensive public consultations about the future of the NHS in England.
The study published on 16 May underscores the public's desire for a redistribution of NHS resources. If the NHS budget remains unchanged, 60 per cent of those
polled believe the government should focus on improving access to community-based services like general practice and dentistry.
The Royal Pharmaceutical Society (RPS) has said that it strongly supports the UK government's proposal that individuals born on or after 1 January 2009
should be prohibited from legally purchasing tobacco products.
It has also shown its agreement to several other actions proposed by the Department of Health and Social Care's (DHSC) for 'Creating a Smokefree Generation and
Tackling Youth Vaping' including:
The inclusion of all tobacco products, cigarette papers, and herbal smoking products in the new legislation.
Restrictions on the sale and supply of disposable vapes, and vape flavours.
RPS President, Professor Claire Anderson, said: "Our recommendations reflect a commitment to creating a future free from the harms of tobacco and youth vaping.
It's crucial to prohibit access for the youngest generation, regulate all tobacco-related items, and address the allure of flavoured e-cigarettes."
The National Institute for Health and Care Excellence (NICE) has recommended icosapent ethyl also called Vazkepa manufactured by Amarin for adults who have cardiovascular disease with controlled LDL-C levels taking a statin.
It's final draft guidance is expected to be available on the July 20.
Nearly half a million people are expected to benefit from the first licensed treatment shown to reduce the risk of heart attacks and strokes in people with
controlled low-density lipoprotein cholesterol (LDL-C - sometimes called "bad" cholesterol) who are taking a statin and who have raised levels of triglycerides.
NICE said: "Clinical trial evidence suggests that for people with raised triglycerides who have LDL-C levels controlled by statins, and who have cardiovascular disease, icosapent ethyl reduces their risk of cardiovascular events by over a quarter compared with placebo.
Helen Knight, interim director of medicines evaluation at NICE, said: "Icosapent ethyl is the first licensed treatment of its kind for people who are at risk of heart attacks and strokes despite well controlled LDL cholesterol because they have raised blood fats. And although lifestyle changes, including diet and exercise, can help to reduce their risk, these may not work for everyone.
In recent years, the healthcare sector has seen a significant transformation driven by the rapid advancement of technology. From improved patient care to
streamlined administrative processes, technology has become an indispensable part of modern healthcare. As medical facilities worldwide embrace these innovations,
it's essential to understand why the sector leans so heavily on advanced technological solutions. Below are seven key reasons illustrating the crucial role of
technology in healthcare.
Enhanced Radiology Workflows
Advancements in technology have revolutionized radiology workflows, making the process more efficient and accurate. Digital imaging technologies, such as
PACS (Picture Archiving and Communication Systems) and RIS (Radiology Information Systems), allow for the seamless storage, retrieval, and sharing of medical
images. The specialists AbbaDox say that this reduces the time needed to diagnose and treat patients, significantly improving the overall efficiency of radiology
departments. Additionally, AI-powered tools can assist radiologists by highlighting potential areas of concern within images, ensuring that abnormalities are not
overlooked. These improvements contribute to faster, more accurate diagnoses and better patient outcomes.
The NHS has launched plans to expand pioneering subscription-style drug contracts to develop lifesaving antibiotics of the future.
It is building on its world-first pilot to incentivise the pharmaceutical industry to develop new antibiotics that could be offered to NHS patients when they
need them the most.
The consultation has launched almost a year to the day that contracts for two superbug-busting drugs were rolled out as part of a world-first pilot.
Cefiderocol and ceftazidime-avibactam, new antibiotics manufactured by Shionogi and Pfizer respectively, were awarded world-first subscription contracts which
provided the companies with a fixed annual fee based primarily on the availability of the drugs and their value to the NHS, as opposed to the volumes used.
By breaking the link between the payments companies receive and the number of their antibiotics prescribed, the NHS is removing any incentive to overuse antibiotics,
decreasing the risk of life-threatening infections, such as sepsis and pneumonia, becoming resistant to treatment.
The Department of Health and Social Care (DHSC) has announced 30 pence increase in prescription charges from £9.35 to £9.65 for each medicine or appliance
dispensed.
Board Chair for England at RPS, Thorrun Govind commented: "This is a kick in the teeth for people in England who are already struggling with rising bills and food
prices.
"Patients groups have warned that people are not collecting prescription medicines due to cost and pharmacists are seeing this worrying trend first-hand.
"A Government impact assessment noted the risk of adverse effects of people not taking their medicines, resulting in future health problems for the individual,
potential hospital admissions, and a subsequent cost to the NHS.
"This decision seems to prioritise revenue generation over ill-health prevention and undermines the principle of an NHS free at the point of use.
The UK Health Security Agency (UKHSA) and The Pirbright Institute have launched a new collaboration to develop vaccines against henipavirus, a genus of
viruses that includes Nipah virus.
Funded by the Medical Research Council, this research aims to develop a vaccine that provides cross protection against the whole genus, addressing the threat of
outbreaks from new or emerging henipaviruses and strengthening epidemic preparedness.
Scientists at UKHSA will evaluate the protective efficacy of vaccines developed by The Pirbright Institute by using use a model of Nipah virus disease, which
mimics the infection in humans.
Professor Isabel Oliver, chief scientific officer at UKHSA, stated that the study would improve understanding of henipaviruses and enhance efforts to protect
health from this "current and future global health threat."
"The work will also make a vital contribution to the 100 Days Mission - an important initiative to make sure the world is better prepared for the next pandemic
by accelerating the development of diagnostics, therapeutics and vaccines," he added.
A new bill was introduced to Parliament on Wednesday (20 March) to prohibit the sale of tobacco to children under the age of 15, delivering on the
Prime Minister's commitment to create a smokefree generation.
The Tobacco and Vapes Bill aims to protect future generations from the harmful impacts of smoking, thereby saving thousands of lives and billions of pounds
for the NHS.
The bill will also introduce new powers to restrict vape flavours and packaging deliberately targeted towards children, as well as allow the government to
change how they are displayed in shops, moving them out of sight of children and away from products that appeal to them, like sweets.
Additionally, enforcement officers' powers will be strengthened with 'on the spot fines' of £100 to ensure compliance with the new laws. This complements
the existing maximum fine of £2,500 that local authorities can already impose. It will also become illegal to provide free samples of vapes to children under
the age of 18.
The number of people living to be 100 or more increased by 3.7 per cent in England and Wales in 2022, compared to the previous year, according to new
figures from the Office for National Statistics (ONS).
ONS data also revealed that the number of centenarians in the UK has more than doubled in the last two decades.
Wales has more centenarians (27 people per 100,000 aged 100 or over) than England (25 people per 100,000).
It's good news that more people are living into their second century, but it also means that we may need to rethink our health plans for a longer future, a leading
testing expert has suggested.
The government has allocated an additional 350 medical school places in England, making a significant step in delivering the NHS Long Term Workforce Plan.
Supported by more than £2.4 billion in government funding, the plan outlines the strategy for recruiting and retaining hundreds of thousands more staff over the
next 15 years to deliver the future workforce the NHS requires.
One of the key commitments of the NHS Long Term Workforce Plan is to double the number of medical school places in England to 15,000 by 2031.
As part of the ongoing efforts to fulfill this pledge, the Office for Students (OfS) has designated 350 places for medical schools nationwide for the academic year
2025 to 2026, targeting under-doctored areas.
The Self-Care Strategy Group (SCSG) has written to Health Secretary, Wes Streeting, urging the new Labour government to fully realize self-care's benefits.
With PAGB serving as the secretariat for the Group, signatories of the letter also include CPE, RPS, CCA, NPA, the Dispensing Doctors' Association, the National
Association of Primary Care, the Patient Information Forum, and the Self Care Forum.
The nine members highlight the importance of collaborative efforts to build an NHS fit for the future.
In the letter, the group emphasises the potential of self-care to alleviate pressure on primary and emergency healthcare services.
They call for expanded prescribing rights, optimised digital health tools, and streamlined referral processes between primary, diagnostic, and specialist care
services.
The UK government will lay legislation today (13 December 2023) to allow the General Medical Council (GMC) to begin the process of regulating medical
associates to expand their roles in the NHS.
This will support plans to reduce pressure on doctors and GPs and improve access for patients, the Department of Health and Social Care (DHSC) said.
Physician associates (PAs) and anaesthesia associates (AAs) will have the same levels of regulatory oversight and accountability as doctors and other regulated
healthcare professionals once the regulations come into force, which is expected at the end of 2024.
The GMC will design and deliver detailed regulatory processes for registration, education, standards and fitness to practise for both professions.
With more than half of the UK population experiencing gum problems and many not believing their condition warrants treatment, there is a significant need for
an oral care range that promotes good gum health and prevents future issues.
Corsodyl is set to launch a new Gum Strength & Protect line, featuring two toothpastes and a daily mouthwash which are clinically proven to protect against gum
problems.
This range aims to meet the growing consumer demand for oral care solutions that help proactively manage gum health and prevent issues related to poor oral hygiene.
The Corsodyl Gum Strength & Protect line is designed to strengthen the gum seal around teeth, offering long-lasting protection.
The product is enriched with hyaluronic acid, a key building block for strong gums, and includes IPMP (Isopropyl Methylphenol) and zinc as antibacterial active
ingredients.
As the countdown to the next UK election begins, the King's Fund has identified three priorities to improve public health.
The national action would be taken by the future government to fix the "NHS and social care" in the country.
The health policy think tank said it would prioritise "improving access to out-of-hospital care", making "careers in health and social care" more attractive
and tackling the biggest risk factors affecting people's health.
It highlighted that workforce crisis is one of the biggest challenges faced by the National Health Service (NHS) and social care services in England while
citing "years of poor planning and fragmented responsibilities" as the reason for widespread staff shortages.
As per the King's Fund's data, there were more than 125,000 vacancies across the NHS workforce in England in October 2023, not including primary care vacancies
such as GPs, and 152,000 vacant posts in the adult social care workforce.